← All trials
NCT05229809
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2022
- Primary completion
- Jul 31, 2023
- Completion date
- Jul 31, 2024
- First posted
- Feb 8, 2022
- Last posted
- Nov 2, 2022
- Enrollment
- 212
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- China Academy of Chinese Medical SciencesLead sponsor
- China Academy of Chinese Medical SciencesOverall official - principal investigator
- China Academy of Chinese Medical SciencesOverall official - principal investigator
- China Academy of Chinese Medical SciencesSponsor investigator
- China Academy of Chinese Medical SciencesStudy director
- Shanghai University of Traditional Chinese MedicineOverall official - principal investigator
- Guangzhou UniversityOverall official - principal investigator
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Jiangsu UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.